2. Search Result
Search Result
Results for "

Alzheimer diseases

" in MedChemExpress (MCE) Product Catalog:

1761

Inhibitors & Agonists

13

Screening Libraries

18

Fluorescent Dyes

21

Biochemical Assay Reagents

145

Peptides

55

Inhibitory Antibodies

279

Natural
Products

78

Isotope-Labeled Compounds

13

Click Chemistry

12

Oligonucleotides

3

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W015229
    3-Indolepropionic acid
    5+ Cited Publications

    Indole-3-propionic acid; 3-IPA

    		 Endogenous Metabolite Reactive Oxygen Species (ROS) Neurological Disease Metabolic Disease
    3-Indolepropionic acid is shown to be a powerful antioxidant and has potential in the treatment for Alzheimer’s disease.
    3-Indolepropionic acid
  • HY-P1061
    Colivelin
    Maximum Cited Publications
    92 Publications Verification

    		 STAT Amyloid-β Neurological Disease
    Colivelin is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro . Colivelin exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease . Colivelin has the potential for the treatment of alzheimer's disease and ischemic brain injury
    Colivelin
  • HY-50682
    Azeliragon
    10+ Cited Publications

    TTP488; PF-04494700

    		 Amyloid-β Neurological Disease Cancer
    Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .
    Azeliragon
  • HY-13410
    Xanomeline oxalate
    5+ Cited Publications

    LY246708 oxalate

    		 mAChR Neurological Disease
    Xanomeline oxalate (LY246708 oxalate) is a potent and selective muscarinic receptor agonist (SMRA) and stimulates phosphoinositide hydrolysis in vivo. Xanomeline oxalate can be used for the research of Alzheimer’s disease .
    Xanomeline oxalate
  • HY-130750
    Phycocyanobilin

    		Reactive Oxygen Species (ROS) Neurological Disease
    Phycocyanobilin, an orally active antioxidative agent, is an effective scavenger for various reactive oxygen species. Phycocyanobilin can be used for the research of Alzheimer’s disease .
    Phycocyanobilin
  • HY-138935
    Iclepertin
    3 Publications Verification

    BI-425809

    		 GlyT Neurological Disease
    Iclepertin (BI-425809) is a potent, selective and orally active glycine transporter 1 (GlyT1) inhibitor. Iclepertin is inactive against GlyT2. Iclepertin can be used for Alzheimer disease and schizophrenia research .
    Iclepertin
  • HY-111263
    NIAD-4
    1 Publications Verification

    		 Fluorescent Dye Amyloid-β Others
    NIAD-4 is a blood-brain barrier permeable fluorophore for optical imaging of amyloid-β (Aβ) in the central nervous system (CNS) for Alzheimer’s disease (AD). NIAD-4 binds to the same Aβ site with the binding affinity (Ki) of 10 nM .
    NIAD-4
  • HY-P1061A
    Colivelin TFA
    Maximum Cited Publications
    92 Publications Verification

    		 STAT Amyloid-β Apoptosis Neurological Disease
    Colivelin TFA is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro . Colivelin TFA exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease . Colivelin TFA has the potential for the treatment of alzheimer's disease and ischemic brain injury .
    Colivelin TFA
  • HY-114616
    PBB3

    		Tau Protein Fluorescent Dye Neurological Disease
    PBB3 is a tracer of tau PET. PBB3 can be used to detect levels of tau protein in Alzheimer's disease and non-Alzheimer's disease .
    PBB3
  • HY-117259
    Valiltramiprosate
    1 Publications Verification

    ALZ-801

    		 Amyloid-β Neurological Disease
    ALZ-801 is a potent and orally available small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor, valine-conjugated proagent of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound . ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer’s disease .
    Valiltramiprosate
  • HY-Y0399
    L-Norvaline

    Norvaline

    		 Amyloid-β TNF Receptor Arginase Neurological Disease Metabolic Disease
    L-Norvaline is the inhibitor for arginase, that promotes the production of NO, reduces oxidative stress, improves insulin resistance, and exhibits antioxidant and anti-hyperglycemic effects. L-Norvaline can be used in research of Alzheimer’s disease .
    L-Norvaline
  • HY-109052
    Atabecestat
    1 Publications Verification

    JNJ-54861911

    		 Beta-secretase Neurological Disease
    Atabecestat (JNJ-54861911) is a potent brain-penetrant and orally active β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor, achieves robust and high CSF Aβ reduction. Atabecestat s tolerated and displays a sustained pharmacokinetic (PK) and pharmacodynamic (PD) characteristics. Atabecestat has the potential for Alzheimer's Disease treatment .
    Atabecestat
  • HY-13779
    (E/Z)-J147

    		Monoamine Oxidase Dopamine Transporter Neurological Disease
    (E/Z)-J147 is an exceptionally potent, orally active, neuroprotective agent for cognitive enhancement. (E/Z)-J147 can readily pass the blood brain barrier (BBB). (E/Z)-J147 can inhibit monoamine oxidase B (MAO B) and the dopamine transporter with EC50 values of 1.88 μM and 0.649 μM, respectively. (E/Z)-J147 has potential for the study of Alzheimer’s disease (AD) .
    (E/Z)-J147
  • HY-132582
    Diranersen

    IONIS-MAPTRx; BIIB080; ISIS 814907

    		 Tau Protein Neurological Disease
    Diranersen (IONIS-MAPTRx) is an antisense oligonucleotide that targets the human MAPT gene to inhibit the production of tau protein. Diranersen can be used in research related to Alzheimer's disease and tauopathies .
    Diranersen
  • HY-122487
    Troriluzole

    BHV-4157

    		 mGluR Neurological Disease Cancer
    Troriluzole, a third-generation, tripeptide proagent of Riluzole (HY-B0211), is an orally active glutamate modulator. Troriluzole reduces synaptic glutamate level and increases the synaptic glutamate absorption. Troriluzole has the potential for Alzheimer disease and generalized anxiety disorder (GAD) .
    Troriluzole
  • HY-16361A
    Omigapil maleate

    CGP3466B; CGP3446 maleate; TCH346 maleate

    		 Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology
    Omigapil maleate (CGP3466B), an orally active GAPDH nitrosylation inhibitor, abrogates Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice. Omigapil maleate has the potential for the research of Alzheimer's disease. Omigapil maleate is a apoptosis inhibitor. Omigapil maleate can be used for the research of congenital muscular dystrophy (CMD). Omigapil maleate is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups .
    Omigapil maleate
  • HY-144681
    Ceperognastat

    LY3372689

    		 OGA Tau Protein Neurological Disease
    Ceperognastat (LY3372689) is an orally active O-GlcNAcase (OGA) enzyme inhibitor. Ceperognastat can be used for tauopathies research, including Alzheimer’s disease .
    Ceperognastat
  • HY-P1047
    β-Sheet Breaker Peptide iAβ5

    [Pro18, Asp21] β-Amyloid (17-21)

    		 Amyloid-β Neurological Disease
    β-Sheet Breaker Peptide iAβ5 is an effective brain amyloid-β (Abeta) degrader. Abeta deposits are associated with Alzheimer's disease (AD), and the related toxicity arises from its β-sheet conformation and aggregation. β-Sheet Breaker Peptide iAβ5 can repeatedly induce the degradation of fibrillary amyloid deposits in vivo. Therefore, β-Sheet Breaker Peptide iAβ5 can prevent and/or reverse neuronal contraction caused by Abeta and reduce the range of interleukin IL-1beta positive microglial-like cells around Abeta deposits. β-Sheet Breaker Peptide iAβ5 can reduce the size and/or number of brain amyloid plaques in AD. β-Sheet Breaker Peptide iAβ5 is labeled with a hydrophobic benzyl alcohol (HBA) tag and shows a bright blue color under acidic conditions, which can be used for quantitative determination.
    β-Sheet Breaker Peptide iAβ5
  • HY-136500
    Prostaglandin H2

    PGH2

    		 Endogenous Metabolite Amyloid-β Neurological Disease Inflammation/Immunology
    Prostaglandin H2 (PGH2) is an endothelium-derived contracting factor. Prostaglandin H2 can cause vasoconstriction. Prostaglandin H2 is the common precursor of all PGs and is produced by several cells that express cyclooxygen-ases. Prostaglandin H2 can activate PGD2 receptors CRTH2 and DP via interacting directly with the receptors and/or by giving rise to PGD2 after catalytic conversion by plasma proteins. Prostaglandin H2 can induce eosinophils migration and inhibit platelet aggregation. Prostaglandin H2 can accelerate the formation of dimers and higher oligomers of amyloid β1-42. Prostaglandin H2 can be used for the researches of inflammation and neurological disease, such as Alzheimer disease .
    Prostaglandin H2
  • HY-14679
    GSK3β inhibitor II

    		GSK-3 Neurological Disease
    GSK3β inhibitor II is an inhibitor of GSK3β. GSK3β inhibitor II can be used for research of Alzheimer’s disease (AD) .
    GSK3β inhibitor II
  • HY-10096
    TCS2002

    		GSK-3 Neurological Disease
    TCS2002 (Compound 9b) is a highly selective, orally bioavailable and potent GSK-3β inhibitor with the IC50 of 35 nM. TCS2002 shows good pharmacokinetic profiles including favorable BBB penetration. TCS2002 can be used for the research of Alzheimer’s disease .
    TCS2002
  • HY-117924
    AUTEN-67

    Autophagy enhancer-67

    		 Autophagy Neurological Disease
    AUTEN-67 (Autophagy enhancer-67) is an orally active autophagy enhancer and MTMR14 inhibitor. AUTEN-67 has anti-aging and neuroprotective effects. AUTEN-67 protects neurons from stress-induced cell death. AUTEN-67 also restores nesting behavior in a mice model of Alzheimer disease .
    AUTEN-67
  • HY-167843
    Alborixin

    		Akt Autophagy PTEN Amyloid-β Antibiotic Bacterial Fungal Infection Neurological Disease
    Alborixin is a polycyclic polyether ionophore Antibiotic. Alborixin is isolated from cultures of Streptomyces albus. Alborixin induces Autophagy via PTEN-mediated inhibition of the AKT pathway, thereby clearing Amyloid-β. Alborixin exhibits activity against Gram-positive bacteria and fungi. Alborixin can be used in the research of Alzheimer's disease .
    Alborixin
  • HY-101710
    Benzgalantamine

    GLN-1062

    		 Drug Intermediate Neurological Disease
    Benzgalantamine (GLN-1062) is a pro-agent of galantamine, used for the treatment for Alzheimer’s disease.
    Benzgalantamine
  • HY-176892
    Papaveroline

    		Src Neurological Disease
    Papaveroline is an orally active Fyn tyrosine kinase inhibitor. Papaveroline stably binds to the active site of Fyn tyrosine kinase via hydrogen bonding and hydrophobic interactions, thereby inhibiting kinase activity associated with the pathogenesis of Alzheimer's disease. Papaveroline can be used for the research of Alzheimer's disease .
    Papaveroline
  • HY-111560
    IQM-266

    		Potassium Channel Neurological Disease
    IQM-266 is a Downstream Regulatory Element Antagonist Modulator (DREAM) ligand with a KD of 4.63 μM. IQM-266 inhibits the KV4.3/DREAM current in a concentration-, voltage-, and time-dependent-manner. IQM-266 also modulates A-type outward potassium currents (IA) from rat dorsal root ganglia (DRG) neurons. IQM-266 can be used for neurological disease research, such as Alzheimer’s disease and Huntington's disease (HD) .
    IQM-266
  • HY-P2912
    Glutamate dehydrogenase (NADP)

    		Glutamate Dehydrogenase (GLDH) Biochemical Assay Reagents Neurological Disease
    Glutamate dehydrogenase (NADP) is the catalytic enzyme for glutamate production. Dysfunction of Glutamate dehydrogenase (NADP) may induce various neurodegenerative diseases, such as Parkinson's disease, epilepsy, Alzheimer's disease, schizophrenia, and frontotemporal dementia. Glutamate dehydrogenase (NADP) can be used in research on neurological diseases such as Parkinson's disease, epilepsy, and Alzheimer's disease .
    Glutamate dehydrogenase (NADP)
  • HY-172967
    SARM1-IN-5

    		Toll-like Receptor (TLR) Neurological Disease
    SARM1-IN-5 (compound 1-23-a) is a SARM1 inhibitor. SARM1-IN-5 can be used in the study of axonal degeneration related diseases such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS) .
    SARM1-IN-5
  • HY-P4704A
    α-Synuclein (61-95) (human) TFA

    		α-synuclein Neurological Disease
    α-Synuclein (61-95) (human) TFA is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) TFA can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .
    α-Synuclein (61-95) (human) TFA
  • HY-Y0399R
    L-Norvaline (Standard)

    		Amyloid-β Reference Standards TNF Receptor Arginase Neurological Disease Metabolic Disease
    L-Norvaline (Standard) is the analytical standard of L-Norvaline (HY-Y0399). This product is intended for research and analytical applications. L-Norvaline is the inhibitor for arginase, that promotes the production of NO, reduces oxidative stress, improves insulin resistance, and exhibits antioxidant and anti-hyperglycemic effects. L-Norvaline can be used in research of Alzheimer’s disease .
    L-Norvaline (Standard)
  • HY-100723
    THK-523

    		Amyloid-β Neurological Disease
    THK-523 has demonstrated its high affinity and selectivity for tau pathology both in vitro and in vivo. 18F-THK523 is a potent tau imaging radiotracer. 18F-THK523 is a potent in vivo tau imaging ligand for Alzheimer's disease .
    THK-523
  • HY-144389
    hAChE/Aβ1-42-IN-1

    		Cholinesterase (ChE) Amyloid-β Neurological Disease
    hAChE/Aβ1-42-IN-1 (Compound 16) is a potent inhibitor of hAChE and Aβ1-42 aggregation. hAChE/Aβ1-42-IN-1 shows acceptable relative safety upon hepG2 cell line and excellent BBB penetration with wide safety margin. hAChE/Aβ1-42-IN-1 has the potential for the research of Alzheimer disease (AD) .
    hAChE/Aβ1-42-IN-1
  • HY-178323
    MW073

    		5-HT Receptor Arrestin Neurological Disease
    MW073 is a highly selective and orally active 5-HT2BR antagonist (IC50 =70 nM). MW073 exerts its effects by concentration-dependently inhibiting receptor activity and β-arrestin-1 recruitment. MW073 ameliorates synaptic plasticity and behavioral deficits, including aggression, in Alzheimer’s disease (AD) mouse models. MW073 can be used for Alzheimer’s disease (AD) research [1][2].
    MW073
  • HY-172427
    Elsovaptan

    		Vasopressin Receptor Neurological Disease
    Elsovaptan is the antagonist for vasopressin receptor that can be used in researchs of Alzheimer disease .
    Elsovaptan
  • HY-P1362A
    β-Amyloid (42-1), human TFA

    Amyloid β Peptide (42-1)(human) TFA

    		 Amyloid-β Neurological Disease
    β-Amyloid (42-1), human TFA is the inactive form of Amyloid β Peptide (1-42). β-Amyloid (42-1), human TFA is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease .
    β-Amyloid (42-1), human TFA
  • HY-P1051
    β-Amyloid (12-28)

    Amyloid β-Protein (12-28)

    		 Amyloid-β Neurological Disease
    β-Amyloid (12-28) (Amyloid β-Protein (12-28)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) shows aggregation properties. β-Amyloid (12-28) has the potential for Alzheimer’s disease research .
    β-Amyloid (12-28)
  • HY-145712
    ElteN378

    		FKBP Cancer
    ElteN378 is an inhibitors of FKBP12e. ElteN378 can be used in study Alzheimer disease, Parkinson disease, Amyotrophic Lateral Sclerosis, proliferation disorders and cancer .
    ElteN378
  • HY-P991886
    ANX-M1 (Human IgG1)

    		Complement System Neurological Disease
    ANX-M1 is a blood-brain barrier-permeable anti-C1q antibody. ANX-M1 can slow down the progression of retinal degeneration following photo-oxidative damage. ANX-M1 has been incorporated into nanocarriers to evaluate its brain delivery efficacy in a mouse model of Alzheimer's disease. ANX-M1 is applicable for research on age-related macular degeneration and Alzheimer's disease [1] .
    ANX-M1 (Human IgG1)
  • HY-P991536
    KHK6640

    		Amyloid-β Neurological Disease
    KHK6640 is a humanized anti-amyloid beta oligomer-specific antibody. KHK6640 demonstrates high potency and efficacy for cognitive improvement in several rodent Alzheimer’s models. KHK6640 can be studied in research for neurological diseases such as Alzheimer’s disease .
    KHK6640
  • HY-N15649
    Ostruthol

    		Cholinesterase (ChE) Neurological Disease
    Ostruthol is a coumarin and a potent inhibitor of AChE. Ostruthol can be studied in research on Alzheimer’s disease .
    Ostruthol
  • HY-134894A
    Glycerophosphorylethanolamine sodium

    GroPEtn sodium

    		 Amyloid-β Neurological Disease
    Glycerophosphorylethanolamine (GroPEtn) sodium is an active phosphodiester metabolite of Phosphatidylethanolamine. Glycerophosphorylethanolamine sodium promotes the aggregation of amyloid β-protein (Aβ (1-40)) in vitro. Glycerophosphorylethanolamine sodium can be used in the field of neurodegenerative diseases, such as Alzheimer’s disease research .
    Glycerophosphorylethanolamine sodium
  • HY-P4704
    α-Synuclein (61-95) (human)

    		α-synuclein Neurological Disease
    α-Synuclein (61-95) (human) is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .
    α-Synuclein (61-95) (human)
  • HY-146068
    AEP-IN-1

    		Cathepsin Neurological Disease
    AEP-IN-1 (Compound 13e) is a CNS agent-like non-covalent inhibitor of asparagine endopeptidase (AEP), with the IC50 of 89 nM. AEP-IN-1 can be used for the research of numerous neurological diseases such as Alzheimer’s disease (AD) .
    AEP-IN-1
  • HY-172143
    ATUX-8385

    		Phosphatase Neurological Disease Cancer
    ATUX-8385 is a potent PP2A activator. ATUX-8385 binds to PR65 subunit. ATUX-8385 has the potential for the research of cancers and chronic conditions such as Alzheimer’s disease and chronic obstructive pulmonary disease .
    ATUX-8385
  • HY-180448
    Galactamine

    		Cholinesterase (ChE) Neurological Disease
    Galactamine is an AChE inhibitor. Galactamine can be used in the research of Alzheimer's disease .
    Galactamine
  • HY-15115
    SUAM 1221

    		Prolyl Endopeptidase (PREP) Neurological Disease
    SUAM 1221 is a prolyl endopeptidase inhibitor. CS-0777 can be used in the research of Alzheimer diseases .
    SUAM 1221
  • HY-P1060
    LPYFD-NH2

    		Amyloid-β Neurological Disease
    LPYFD-NH2, a pentapeptide, exerts some inhibitory effect on the aggregation of Aβ(1-42). LPYFD-NH2 can be used for the research of Alzheimer’s disease .
    LPYFD-NH2
  • HY-P1060A
    LPYFD-NH2 TFA

    		Amyloid-β Neurological Disease
    LPYFD-NH2 TFA, a pentapeptide, exerts some inhibitory effect on the aggregation of Aβ(1-42). LPYFD-NH2 TFA can be used for the research of Alzheimer’s disease .
    LPYFD-NH2 TFA
  • HY-106933A
    Dabelotine methanesulfonate

    S 12024-2

    		 Adrenergic Receptor Neurological Disease
    Dabelotine (methanesulfonate) is a cognitive enhancer. Dabelotine (methanesulfonate) can be used for Alzheimer disease (AD) research .
    Dabelotine methanesulfonate
  • HY-13410R
    Xanomeline oxalate (Standard)

    LY246708 oxalate (Standard)

    		 mAChR Reference Standards Neurological Disease
    Xanomeline (oxalate) (Standard) is the analytical standard of Xanomeline (oxalate). This product is intended for research and analytical applications. Xanomeline oxalate (LY246708 oxalate) is a potent and selective muscarinic receptor agonist (SMRA) and stimulates phosphoinositide hydrolysis in vivo. Xanomeline oxalate can be used for the research of Alzheimer’s disease .
    Xanomeline oxalate (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: